← Back to Home

Restoring Mutant p53 Function: PMV Plans to Seek Approval for Ovarian Cancer Drug in 2027

Rezatapopt showed signs of tumor shrinkage in ovarian cancer patients with a specific TP53 mutation, prompting the company to prepare an accelerated approval application; however, the interim response rate still cannot answer whether it extends survival.

By SURL BioNews

Can an oral drug reactivate the growth brakes that cancer cells have lost? Rezatapopt, developed by PMV Pharmaceuticals, aims to restore the tumor-suppressing function of mutant p53 protein. On August 31, the company announced interim results from a Phase 2 ovarian cancer trial and said it plans to apply to the U.S. Food and Drug Administration (FDA) for accelerated approval in the first quarter of 2027.

The application targets ovarian cancer with the TP53 Y220C mutation that is resistant to or does not respond to platinum-based chemotherapy. PMV said feedback from a recent meeting with the FDA supports its filing strategy; however, this is the company’s account of the communication and does not mean the regulator has accepted an application or committed to approval.

p53 helps regulate cellular responses to damage and abnormal growth, and mutations may weaken this defense. Rezatapopt, also known as PC14586, is designed to bind to a specific pocket in the Y220C mutant protein, stabilize its structure, and attempt to restore normal tumor-suppressing function. It targets a defined molecular alteration, and its efficacy cannot be directly generalized to all cancers with TP53 mutations.

The multicenter, single-arm Phase 2 trial, called PYNNACLE, evaluates rezatapopt as monotherapy at an oral dose of 2,000 milligrams once daily. As of May 14, 2026, the ovarian cancer efficacy analysis included 76 patients; according to investigator assessments, 35 had a tumor response, for an overall response rate of 46%. These included 4 patients with confirmed complete responses, 29 with confirmed partial responses, and another 2 whose partial responses remained unconfirmed.

Among patients with confirmed responses, the median duration of response was 10 months. This figure describes how long a response was maintained after tumor shrinkage, rather than the duration of disease control or survival for all participants. The trial has no randomized control group, so these results also cannot establish that the drug is superior to existing treatments.

On safety, the company said treatment-related adverse events across the cancer cohorts were mostly Grade 1 or 2. The overall rate of discontinuation due to treatment-related adverse events was 5%, and findings in the ovarian cancer cohort were similar to those overall. The announcement provides aggregate results, which are not yet sufficient to fully characterize the range of side effects and the burden of long-term treatment.

For this tumor-suppressing pathway, which has long been difficult to target with drugs, the interim data provide a basis for further development. A complete efficacy analysis, longer follow-up, and regulatory review will determine whether the tumor-shrinkage signal can translate into an available treatment option for this specific group of patients.

References

  1. pharmaphorum